Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Stefan G. van Ravensteijn"'
Autor:
Stefan G. van Ravensteijn, Maikel J. L. Nederkoorn, Tom C. P. Wal, Yvonne M. H. Versleijen-Jonkers, Pètra M. Braam, Uta E. Flucke, Johannes J. Bonenkamp, Bart H. W. Schreuder, Carla M. L. van Herpen, Johannes H. W. de Wilt, Ingrid M. E. Desar, Jacky W. J. de Rooy
Publikováno v:
Cancers, Vol 15, Iss 10, p 2843 (2023)
To improve local control, neoadjuvant radiotherapy (nRT) followed by surgery is the standard of care in myxofibrosarcoma (MFS) because of its infiltrative growth pattern. Nevertheless, local recurrence rates are high. Data on prognostic factors for p
Externí odkaz:
https://doaj.org/article/eb27bde892b548d687d08aaab4b4fe6e
Autor:
Stefan G. van Ravensteijn, Yvonne M. H. Versleijen-Jonkers, Melissa H. S. Hillebrandt-Roeffen, Marije E. Weidema, Maikel J. L. Nederkoorn, Kalijn F. Bol, Mark A. J. Gorris, Kiek Verrijp, Leonie I. Kroeze, Tessa J. J. de Bitter, Richarda M. de Voer, Uta E. Flucke, Ingrid M. E. Desar
Publikováno v:
Cancers, Vol 14, Iss 23, p 5938 (2022)
Angiosarcomas (AS) are extremely rare and aggressive vascular malignancies subdivided in de novo primary AS (pAS) and secondary AS (sAS). We hypothesize that the combination of immunological and genomic profiles significantly differs between primary
Externí odkaz:
https://doaj.org/article/5be8092c919940ac829d3543a62c1238
Autor:
Stefan G. van Ravensteijn, Mirte Meijerink, Renée Nijenhuis-van Schayk, Ingrid M.E. Desar, Kalijn F. Bol, Carla M.L. van Herpen, Henk M.W. Verheul
Publikováno v:
European Journal of Cancer, 183, 90-94. Elsevier Ltd.
European Journal of Cancer, 183, pp. 90-94
van Ravensteijn, S G, Meijerink, M, Nijenhuis-van Schayk, R, Desar, I M E, Bol, K F, van Herpen, C M L & Verheul, H M W 2023, ' The safety risk of information overload and bureaucracy in oncology clinical trial conduct ', European Journal of Cancer, vol. 183, pp. 90-94 . https://doi.org/10.1016/j.ejca.2023.01.018
European Journal of Cancer, 183, 90-94. Pergamon
European Journal of Cancer, 183, 90-94
European Journal of Cancer, 183, pp. 90-94
van Ravensteijn, S G, Meijerink, M, Nijenhuis-van Schayk, R, Desar, I M E, Bol, K F, van Herpen, C M L & Verheul, H M W 2023, ' The safety risk of information overload and bureaucracy in oncology clinical trial conduct ', European Journal of Cancer, vol. 183, pp. 90-94 . https://doi.org/10.1016/j.ejca.2023.01.018
European Journal of Cancer, 183, 90-94. Pergamon
European Journal of Cancer, 183, 90-94
Contains fulltext : 290766.pdf (Publisher’s version ) (Closed access) Performance of clinical trials has led to major therapeutic developments and substantial improvements in the field of medical oncology. To ensure patient's safety, regulatory asp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::541d1fe4782a72ae858467a5e22fc450
https://pure.eur.nl/en/publications/a5fc8a91-3cd9-4b9f-9350-82677851fc7b
https://pure.eur.nl/en/publications/a5fc8a91-3cd9-4b9f-9350-82677851fc7b
Autor:
Maike JM Uijen, Jetty AM Weijers, Gerben Lassche, Stefan G van Ravensteijn, Maartje C van Rijk, Satish FK Lubeek, Adriana CH van Engen-van Grunsven, Avital Amir, Chantal ML Driessen, Carla ML van Herpen
Publikováno v:
Journal of Clinical Pathology : the Journal of the Association of Clinical Pathologists, 76, 3, pp. 211-213
Journal of Clinical Pathology : the Journal of the Association of Clinical Pathologists, 76, 211-213
Journal of Clinical Pathology : the Journal of the Association of Clinical Pathologists, 76, 211-213
Item does not contain fulltext
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6893d44573aa33a7b75d17f834372390
https://repository.ubn.ru.nl/handle/2066/290739
https://repository.ubn.ru.nl/handle/2066/290739
Autor:
Stefan G. van Ravensteijn, Yvonne M. Versleijen-Jonkers, Melissa H. Hillebrandt-Roeffen, Maikel Nederkoorn, Mark A. Gorris, Kiek Verrijp, Leonie I. Kroeze, Tessa J. de Bitter, Richarda M. de Voer, Uta E. Flucke, Ingrid M. Desar
Publikováno v:
Cancer Research. 82:LB140-LB140
Background: Angiosarcomas (AS) are a rare heterogenous group of soft tissue sarcomas (STS) that form in the lining of blood vessels or lymphatic vessels. They comprise of primary (de novo) AS and secondary AS. The etiology of primary AS is unknown. S